CA
NZ
UK
AU
IND
US
…
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
DiaMedica Therapeutics Inc is a clinical-stage biopharma developing biologic therapies for acute ischemic stroke and kidney disease, principally a recombinant human kallikrein candidate (DM199). Long-term growth drivers include positive clinical outcomes, regulatory approvals and commercial partnerships in areas of high unmet need; investors may be attracted by potential first-in-class opportunity and pipeline optionality.
Key risks are high clinical and regulatory development risk, no meaningful product revenue, and dependence on external financing with potential equity dilution.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -32.74M | -24.41M | -19.34M | -13.65M | -13.56M |
| Net income | -32.77M | -24.44M | -19.38M | -13.68M | -13.59M |
| Selling general administrative | 9.78M | 7.43M | 7.96M | 6.16M | 4.88M |
| Selling and marketing expenses | - | 0.19M | 0.20M | - | - |
| Gross profit | - | -0.04M | -0.03M | - | - |
| Reconciled depreciation | 0.04M | 0.04M | 0.03M | 0.03M | 0.02M |
| Ebit | -34.40M | -26.68M | -21.27M | -14.00M | -13.65M |
| Ebitda | -34.35M | -26.64M | -21.24M | -13.98M | -13.62M |
| Depreciation and amortization | 0.04M | 0.04M | 0.03M | 0.03M | 0.02M |
| Operating income | -34.40M | -26.68M | -21.27M | -14.00M | -13.65M |
| Other operating expenses | 34.40M | 26.68M | 21.27M | 14.00M | 13.65M |
| Interest expense | - | - | - | 0.35M | 0.08M |
| Tax provision | 0.03M | 0.03M | 0.03M | 0.03M | 0.03M |
| Income tax expense | 0.03M | 0.03M | 0.04M | 0.03M | 0.03M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 34.40M | 26.68M | 21.27M | 14.00M | 13.65M |
| Cost of revenue | - | 0.04M | 0.03M | - | - |
| Total other income expense net | 1.66M | 2.27M | 1.93M | 0.35M | 0.08M |
| Net income from continuing ops | -32.77M | -24.44M | -17.97M | -13.68M | -13.59M |
| Net income applicable to common shares | - | - | - | - | -13.59M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 61.37M | 46.34M | 54.16M | 34.40M | 45.55M |
| Other current assets | 0.48M | 0.23M | 0.41M | 0.25M | 0.08M |
| Total liab | 5.26M | 5.63M | 3.10M | 2.57M | 1.53M |
| Total stockholder equity | 56.11M | 40.72M | 51.06M | 31.83M | 44.02M |
| Other current liab | 3.54M | 4.35M | 1.78M | 1.36M | 0.97M |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -172.77M | -140.00M | -115.56M | -96.18M | -82.50M |
| Other assets | - | - | 0.00M | - | - |
| Cash | 15.65M | 3.02M | 4.54M | 4.73M | 4.71M |
| Total current liabilities | 5.13M | 5.39M | 2.79M | 2.17M | 1.52M |
| Net debt | -15.41M | -2.69M | -4.14M | -4.26M | -4.66M |
| Short term debt | 0.11M | 0.10M | 0.08M | 0.07M | 0.05M |
| Short long term debt total | 0.24M | 0.34M | 0.40M | 0.47M | 0.05M |
| Other stockholder equity | 228.83M | 180.70M | 166.61M | 128.08M | 126.58M |
| Property plant equipment | - | - | - | 0.56M | 0.11M |
| Total current assets | 60.63M | 44.61M | 53.67M | 33.84M | 45.44M |
| Net tangible assets | - | - | - | - | 44.02M |
| Short term investments | 44.24M | 41.12M | 48.35M | 28.77M | 40.41M |
| Net receivables | 0.26M | 0.24M | 0.37M | 0.08M | 0.13M |
| Inventory | - | - | - | - | 0.11M |
| Accounts payable | 1.48M | 0.94M | 0.93M | 0.73M | 0.51M |
| Accumulated other comprehensive income | 0.05M | 0.02M | 0.01M | -0.07M | -0.05M |
| Non currrent assets other | 0.40M | 1.31M | -0.00M | - | -40.41M |
| Non current assets total | 0.74M | 1.74M | 0.48M | 0.56M | 0.11M |
| Capital lease obligations | 0.24M | 0.34M | 0.40M | 0.47M | 0.05M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -2.15M | 8.56M | -19.70M | 11.54M | -20.52M |
| Change to liabilities | - | - | - | 0.00M | -0.59M |
| Total cashflows from investing activities | -2.19M | 8.56M | -18.30M | - | -20.54M |
| Net borrowings | -0.01M | -0.01M | -0.01M | -0.01M | -0.01M |
| Total cash from financing activities | 43.88M | 11.99M | 36.84M | -0.01M | 30.09M |
| Change to operating activities | - | - | - | 0.31M | -0.08M |
| Net income | -32.77M | -24.44M | -19.38M | -13.68M | -13.59M |
| Change in cash | 12.62M | -1.52M | -0.18M | 0.02M | -2.70M |
| Begin period cash flow | 3.02M | 4.54M | 4.73M | 4.71M | 7.41M |
| End period cash flow | 15.65M | 3.02M | 4.54M | 4.73M | 4.71M |
| Total cash from operating activities | -29.06M | -22.08M | -18.73M | -11.51M | -12.25M |
| Issuance of capital stock | 43.28M | 11.75M | 36.85M | 0.00M | 29.85M |
| Depreciation | -0.90M | 0.04M | 0.03M | 0.03M | 0.02M |
| Change to account receivables | -0.02M | 0.13M | -0.29M | 0.05M | 0.21M |
| Other cashflows from financing activities | -0.40M | 0.26M | -18.30M | 11.54M | 0.24M |
| Change to netincome | - | - | - | 1.55M | 1.78M |
| Capital expenditures | 0.04M | 0.03M | 0.02M | 0.08M | 0.02M |
| Change in working capital | 0.68M | 1.51M | 0.09M | 0.58M | -0.46M |
| Stock based compensation | 3.85M | 2.08M | 1.68M | 1.50M | 1.56M |
| Other non cash items | 0.08M | -1.27M | -1.15M | 0.05M | 0.06M |
| Free cash flow | -29.10M | -22.10M | -18.75M | -11.59M | -12.27M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| DMAC DiaMedica Therapeutics Inc |
-0.27 2.84% |
9.25 | - | - | 66.68 | 6.17 | 57.48 | -0.96 |
| NVO Novo Nordisk A/S |
0.86 2.20% |
40.00 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
18.88 3.50% |
558.88 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
109.12 13.33% |
927.89 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
301 Carlson Parkway, Minneapolis, MN, United States, 55305
763 496 5454
35
| Name | Title | Year Born |
|---|---|---|
| Mr. Dietrich John Pauls MBA | Pres, CEO & Director | 1971 |
| Mr. Scott B. Kellen C.A. | CFO & Company Sec. | 1965 |
| Dr. Edward G. Calamai Ph.D. | Consulting Head of Manufacturing | NA |
| Dr. Kirsten L. Gruis M.D., M.S. | Chief Medical Officer | 1973 |
| Mr. Dominic R. Cundari | Chief Commercial Officer | 1951 |
| Ms. Julie VanOrsdel Daves CCRP | Sr. VP of Clinical Devel. Operations | NA |
| Mr. Dietrich John Pauls MBA | President, CEO & Director | 1971 |
| Mr. Scott Kellen C.P.A. | CFO & Corporate Secretary | 1965 |
| Dr. Kirsten L. Gruis M.D., M.S. | Independent Consultant | 1973 |
| Ms. Julie VanOrsdel Daves CCRP | Senior Vice President of Clinical Development Operations | 1974 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...